| Covariate modeling in pharmacometrics: General points for consideration K Sanghavi, J Ribbing, JA Rogers, MA Ahmed, MO Karlsson, N Holford, ... CPT: Pharmacometrics & Systems Pharmacology, 2024 | | 2024 |
| Predicting the Long‐Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis A Thorsted, C Zecchin, A Berges, MO Karlsson, LE Friberg Clinical Pharmacology & Therapeutics, 2024 | | 2024 |
| Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea GJ Wellhagen, MO Karlsson, MC Kjellsson, D Garmann, A Bröker, ... CPT: Pharmacometrics & Systems Pharmacology, 2024 | | 2024 |
| Evaluation of covariate effects in item response theory models GJ Wellhagen, A Yassen, D Garmann, A Bröker, A Solms, Y Zhang, ... CPT: Pharmacometrics & Systems Pharmacology, 2024 | 1 | 2024 |
| Properties of the full random‐effect modeling approach with missing covariate data J Nyberg, EN Jonsson, MO Karlsson, J Häggström Statistics in Medicine, 2024 | 3 | 2024 |
| Training the next generation of pharmacometric modelers: a multisector perspective (vol 51, pg 5, 2024) PL Bonate, JS Barrett, S Ait-Oudhia, R Brundage, B Corrigan, S Duffull, ... JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 51 (1), 89-89, 2024 | | 2024 |
| Comparison of Two Methods for Determining Item Characteristic Functions and Latent Variable Time-Course for Pharmacometric Item Response Models L Arrington, MO Karlsson The AAPS Journal 26 (1), 1-11, 2024 | | 2024 |
| Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis M Centanni, ME van de Velde, A Uittenboogaard, GJL Kaspers, ... Clinical Pharmacokinetics 63 (2), 197-209, 2024 | | 2024 |
| Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach A Brekkan, R Lledo-Garcia, B Lacroix, S Jönsson, MO Karlsson, EL Plan Journal of Pharmacokinetics and Pharmacodynamics 51 (1), 65-75, 2024 | | 2024 |
| Training the next generation of pharmacometric modelers: a multisector perspective PL Bonate, JS Barrett, S Ait-Oudhia, R Brundage, B Corrigan, S Duffull, ... Journal of pharmacokinetics and pharmacodynamics 51 (1), 5-31, 2024 | 4 | 2024 |
| Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia M Dam, M Centanni, LE Friberg, D Centanni, MO Karlsson, ... Leukemia, 1-8, 2024 | 1 | 2024 |
| Pharmacogenetic testing or Therapeutic Drug Monitoring: A Quantitative Framework M Centanni, N Reijnhout, A Thijs, M Karlsson, L Friberg | | 2024 |
| Comparative Analysis of Pharmacoeconomic and Pharmacometric Modeling in the Cost-Effectiveness Evaluation of Sunitinib Therapy with Therapeutic Drug Monitoring for … M Centanni, J Nijhuis, M Karlsson, L Friberg | | 2024 |
| Assessment of non-linear mixed effects model-based approaches to test for drug effect using simulated data: type I error and power properties E Chasseloup, A Tessier, MO Karlsson bioRxiv, 2024.04. 13.589388, 2024 | | 2024 |
| Extension of individual model averaging assessments to unbalanced designs and dose-response E Chasseloup, X Li, MO Karlsson bioRxiv, 2024.04. 13.589390, 2024 | | 2024 |
| Efficiency of Multivariate Tests in Trials in Progressive Supranuclear Palsy E Yousefi, M Gewily, F König, G Höglinger, F Hopfner, MO Karlsson, ... arXiv preprint arXiv:2312.08169, 2023 | | 2023 |
| Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children M Centanni, D Elhad, O Zaher, MO Karlsson, LE Friberg | | 2023 |
| Evaluation of the effect of erenumab on migraine‐specific questionnaire in patients with chronic and episodic migraine PW Chen, MO Karlsson, S Ueckert, A Pritchard‐Bell, CP Hsu, S Dutta, ... CPT: Pharmacometrics & Systems Pharmacology 12 (12), 1988-2000, 2023 | | 2023 |
| How to analyze continuous and discrete repeated measures in small-sample cross-over trials? J Verbeeck, M Geroldinger, K Thiel, AC Hooker, S Ueckert, M Karlsson, ... Biometrics 79 (4), 3998-4011, 2023 | 1 | 2023 |
| Increase in PEG-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia B Albertsen, M Dam, M Centanni, L Friberg, D Centanni, M Karlsson, ... | | 2023 |
Andrew C. HookerProfessor of Pharmacometrics, Uppsala UniversityVerified email at farmaci.uu.se
